Pharma wins reduction in data requirements for EU EVMPD product database
This article was originally published in SRA
Following strong lobbying by the pharmaceutical industry, the European Medicines Agency has substantially reduced the amount of information that companies must provide by 2 July on all the products they market in the EU1,2. Industry will be relieved at the move, having pushed hard for a delay to the deadline or at least a reduction in the scope of the requirement.
You may also be interested in...
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.